Bioavailability of Methotrexate (MTX) following different routes of application;Bioverfügbarkeit von Methotrexat (MTX) in unterschiedlichen applikationsarten

Aktuelle Rheumatologie

Volumn 29, Issue 4, 2004, Pages 197-200

  Kabisch, Sadko Armin ^a   Weigand, T ^a   Plischke, H ^b   Menninger, H ^a  

^a Bayerisches Rheuma/Orthopadiezentrum   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Administration; Bioavailability; Intramuscular; Methotrexate MTX; Rheumatoid arthritis; Subcutaneous or oral

Indexed keywords

METHOTREXATE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; EQUIPMENT; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; RHEUMATIC DISEASE;

EID: 4544231057     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813426     Document Type: Conference Paper

References (20)

1. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-1593
2. Dervieux T, Lein DO, Park G et al. Methotrexate polyglutamate concentrations in red blood cells correlates with disease activity and clinical response to methotrexate in rheumatoid arthritis. Arthritis Rheum 2003; 48: 135
3. Herman RA, van Pedersen P, Hoffman J et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-171
4. Hoekstra M, Haagsma C, Neef C et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-648
5. Jundt JW, Browne BA, Fiocco GP et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J. Rheumatol 1993; 20: 1845-1849
6. Kabisch S, Weigand T, Menninger H. Bioverfügbarkeit von Methotrexat (MTX) nach peroraler, intramuskulärer und subcutaner Applikation. Z Rheumatol 2003; 62:1/53
7. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681
8. Körber H, Iven H, Gross WL. Bioavailability and pharmacokinetics of methotrexate and its metabolite 7-hydroxy-MTX after low-dose MTX (25 mg) in patients with chronic rheumatoid diseases. Arthritis Rheum 1992; 35: S142
9. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563
10. Oguey D, Kölliker F, Gerber NJ et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611 -614
11. Petersen KU Generika in der rheumatologischen Pharmakotherapie. Akt Rheumatol 2003; 28:138-143
12. Ranganathan P, Eisen S, Yokoyama WM et al. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003; 62: 4-9
13. Rau R. Methotrexat. In: Rau R(Hrsg). Basistherapie der rheumatoiden Arthritis. Bremen/London/Boston: Uni-Med-Verlag, 2000: 184-207
14. Schneider M, Leigemann M, Abholz HH et al. Management der frühen rheumatoiden Arthritis. Klinische Leitlinie im Auftrag der Deutschen Gesellschaft für Rheumatologie, Fassung Dez. 2003. www.rheumanet.org
15. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 183-190
16. van der Heijde DM, van Leeuwen MA, van Riel PL et al. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792-1796
17. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45
18. Weinblatt ME, Kremer JM, Coblyn JS et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-1328
19. Weisman MH, Bombadier C, Massarotti EM et al. Analysis at one year of an inception cohort of early rheumatoid arthritis: the SONORA study. Arthritis Rheum 2003; 48: S119
20. Zeidler H, Wollenhaupt J. Kombination von Basistherapeutika. Von der individuellen Hoffnung zum gezielten Einsatz. Z Rheumatol 2001; 60: 477-480